Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[11C]CURB is a carbon-11 radiolabeled carbamate radiotracer developed for positron emission tomography (PET) imaging of fatty acid amide hydrolase (FAAH) activity in the brain. It acts as an irreversible inhibitor, selectively targeting and binding to FAAH, the primary enzyme responsible for the degradation of endocannabinoids including anandamide. [11C]CURB uptake in brain tissues demonstrates the regional distribution of FAAH, with high specificity and sensitivity, making it a reliable tool for measuring FAAH activity in vivo for research purposes, including the investigation of neuropsychiatric and neurodegenerative conditions.[1][3][5]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [11C]CURB.